Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $13.87 billion market cap biopharmaceutical company with 18.4% year-over-year revenue growth, appointed Mike Sibley as Senior Vice President and General Manager of its Neuropsychiatry franchise, the company announced Monday.
Sibley, who brings more than 20 years of commercial experience in the biopharmaceutical industry, will develop and execute sales and marketing strategies for the company’s neuropsychiatry products, including the INGREZZA franchise.
Prior to joining Neurocrine, Sibley spent nine years at Sanofi, most recently serving as General Manager for US Dermatology. His previous experience includes roles at Galderma Laboratories, J.P. Morgan Chase & Co., and Johnson & Johnson. He holds a Bachelor of Arts in Economics from the University of Massachusetts, Amherst.
"Mike is an accomplished leader with a strong record of leading high-performing sales and marketing teams and delivering results," said Eric Benevich, Chief Commercial Officer at Neurocrine Biosciences.
Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company’s portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington’s disease-associated chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids.
The information in this article is based on a press release issued by Neurocrine Biosciences.
In other recent news, Neurocrine Biosciences announced strong financial results for the second quarter of 2025. The company experienced significant growth in product sales, notably for its flagship drug, INGREZZA. This growth in sales contributed to robust financial performance for the quarter. Despite these positive results, there was a noted increase in operational costs. These developments were part of recent earnings discussions. No new mergers or acquisitions were reported. Additionally, there were no recent analyst upgrades or downgrades mentioned. Overall, these are the latest updates regarding Neurocrine Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.